Andri L, Senna G, Betteli C, Givanni S, Andri G, Dimitri G, Falagiani P, Mezzelani P
Unit of Clinical Allergology, Verona General Hospital, Italy.
J Allergy Clin Immunol. 1996 Jan;97(1 Pt 1):34-41. doi: 10.1016/s0091-6749(96)70280-4.
Local nasal immunotherapy has been studied, by means of an extract in powder form, in patients with allergic rhinitis caused by grass pollen.
Thirty-two patients allergic to grass were studied for 37 weeks in a double-blind controlled trial. Subjects were selected on the basis of a positive history, skin test result, RAST finding, and result of intranasal challenge to grass pollen. Two 16-patient groups were randomly assigned to active or placebo treatment. The treatment lasted 26 weeks (14 for the build-up phase, 12 for the maintenance period).
No significant differences were observed in nasal symptoms during the treatment. During the pollen season the mean weekly symptom and medication scores were significantly lower in the treated group, compared with the control group, even considering each allergic symptom separately. Moreover, only in the treated group was a significant increase of specific nasal threshold to grass pollen observed after treatment.
This study indicates that local nasal immunotherapy with allergen in powder form can be a suitable alternative to the traditional subcutaneous immunotherapy in terms of clinical efficacy and safety in grass-allergic rhinitis.
已采用粉末状提取物对草花粉引起的变应性鼻炎患者进行了局部鼻内免疫疗法的研究。
在一项双盲对照试验中，对32名对草过敏的患者进行了37周的研究。根据阳性病史、皮肤试验结果、放射变应原吸附试验结果以及对草花粉的鼻内激发试验结果选择研究对象。将32名患者随机分为两组，每组16人，分别接受活性治疗或安慰剂治疗。治疗持续26周（14周为递增期，12周为维持期）。
治疗期间未观察到鼻症状有显著差异。在花粉季节，与对照组相比，治疗组的平均每周症状和用药评分显著更低，即使分别考虑每种过敏症状也是如此。此外，仅在治疗组中观察到治疗后对草花粉的特异性鼻阈值显著升高。
本研究表明，就草过敏性鼻炎的临床疗效和安全性而言，粉末状变应原局部鼻内免疫疗法可能是传统皮下免疫疗法的合适替代方法。
